Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells 2,494 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 2,494 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $172,983.84. Following the completion of the sale, the chief accounting officer owned 70,199 shares in the company, valued at approximately $4,869,002.64. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Thursday, January 8th, Christine Marie Utter sold 1,034 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total transaction of $79,049.30.
• On Wednesday, January 7th, Christine Marie Utter sold 1,235 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.45, for a total transaction of $95,650.75.
• On Tuesday, January 6th, Christine Marie Utter sold 1,381 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $106,267.95.

PTC Therapeutics Stock Up 1.1%

NASDAQ:PTCT traded up $0.76 during trading hours on Friday, reaching $70.66. 2,532,077 shares of the company’s stock were exchanged, compared to its average volume of 1,290,685. The company has a market capitalization of $5.67 billion, a P/E ratio of 8.25 and a beta of 0.48. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The business’s 50-day simple moving average is $75.01 and its two-hundred day simple moving average is $67.78.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). The company had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. PTC Therapeutics’s revenue was down 22.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.85) EPS. As a group, sell-side analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PTCT has been the subject of a number of analyst reports. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of PTC Therapeutics in a report on Friday. Wells Fargo & Company decreased their price objective on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a research note on Friday. TD Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Finally, Bank of America reduced their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a report on Friday. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.73.

Institutional Investors Weigh In On PTC Therapeutics

Several large investors have recently made changes to their positions in PTCT. Vanguard Group Inc. raised its position in PTC Therapeutics by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock valued at $668,691,000 after acquiring an additional 514,204 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of PTC Therapeutics by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock worth $301,856,000 after purchasing an additional 224,481 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of PTC Therapeutics by 28.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock valued at $368,587,000 after purchasing an additional 1,077,776 shares in the last quarter. State Street Corp lifted its stake in shares of PTC Therapeutics by 34.2% in the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after purchasing an additional 1,071,343 shares during the last quarter. Finally, Toronto Dominion Bank lifted its stake in shares of PTC Therapeutics by 27.5% in the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock valued at $314,339,000 after purchasing an additional 891,690 shares during the last quarter.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.